Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDA-cleared ablation technology from RF Innovations, Inc. THE WOODLANDS, TX, July 18, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor "What This ...

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc. THE WOODLANDS, TX, July 18, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This ...

文章核心观点 - 公司的一款用于治疗胰腺癌疼痛的医疗设备在临床试验中取得积极结果 [1][2] - 公司与RF Innovations签署了许可知识产权的最终协议,预计将于本月底完成 [3] - 公司股票在前一交易日大涨130%,成交量大幅增加 [4] - 受前一交易日大涨影响,公司股票在本交易日下跌16.7% [5] 公司概况 - 公司是一家处于发展阶段的医疗设备公司 [1] - 公司专注于开发用于治疗胰腺癌疼痛的医疗设备 [2] - 公司的设备采用射频消融技术来减轻胰腺癌患者的疼痛 [2] 股票表现 - 公司股票在前一交易日大涨130%,成交量大幅增加 [4] - 受前一交易日大涨影响,公司股票在本交易日下跌16.7% [5] - 本交易日公司股票成交量仍低于日均成交量 [6] 其他 - 文章还提到了其他公司的股票动态,但与本文核心内容无关 [7][8]

Medical device firm Autonomix Medical (NASDAQ:AMIX) popped into traders’ radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with RF Innovations, a privately held medical technology specialist, catapulted sentiment. The news established credibility for AMIX stock as the underlying enterprise moves to develop solutions for disorders related to the peripheral nervous system.According to the accompanying press release, the agreement centers on the Apex 6 ...

文章核心观点 - 公司Autonomix与RF Innovations签订协议,获得Apex 6射频消融发生器的非独家全球许可,该发生器已获FDA批准用于疼痛管理 [1][2][3][4] - 该交易有助于简化Autonomix的监管策略,并将该技术应用于公司的治疗领域,以推动其管线的价值 [4] - Autonomix正在开发用于治疗胰腺癌相关疼痛的技术,现有方法如使用阿片类药物或酒精注射只能提供有限缓解,且可能导致严重副作用 [6][8] - Autonomix的技术平台包括一种基于导管的微芯片传感阵列,可检测和区分神经信号,敏感度比现有技术高3000倍,有望实现全身任何部位的血管内诊断和治疗 [7][8] 公司概况 - Autonomix是一家专注于开发创新技术以革新涉及神经系统疾病诊断和治疗方式的医疗器械公司 [7] - 公司正在开发用于治疗疼痛的首创技术,初期临床试验集中于胰腺癌 [6][8] - 该技术平台有望应用于心脏病学、高血压和慢性疼痛管理等多个适应症 [8] - 该技术目前仍处于研发阶段,尚未获得美国FDA的上市批准 [8] 交易信息 - Autonomix以25万股普通股的对价获得Apex 6发生器的永久非独家全球免版税许可 [3] - 该交易有助于简化Autonomix的监管策略,因为Apex 6发生器已获FDA批准用于疼痛管理 [4] - 双方将立即开始合作,将RF Innovations的制造合作伙伴纳入Autonomix的供应链 [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-41940 AUTONOMIX MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer Topline data from first five patients in proof-of-concept (P ...